Regenicin (Regenicin) Net Change in Cash : $-1.66 Mil (TTM As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Regenicin Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Regenicin's Net Change in Cash for the three months ended in Mar. 2023 was $-13.45 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.66 Mil.

Regenicin Net Change in Cash Historical Data

The historical data trend for Regenicin's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Net Change in Cash Chart

Regenicin Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Net Change in Cash

Get a 7-Day Free Trial

-0.02

-0.15

0.01

Regenicin Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Net Change in Cash	Get a 7-Day Free Trial															-	-	0.01	11.78	-13.45

Regenicin Net Change in Cash Calculation

Regenicin's Net Change in Cash for the fiscal year that ended in Sep. 2022 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-0.027	+	0	+	0.04	+	0
	=	0.01

Regenicin's Net Change in Cash for the quarter that ended in Mar. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -0.328 + 0 + -13.119 + 0

= -13.45

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenicin Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Regenicin's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenicin (Regenicin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Net Change in Cash

Comparable Companies

NOVNQ TMBRQ RGRX PCNT NMTRQ ONCSQ QBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY XBRU:ARGX OCSE:GMAB SZSE:300122

Traded in Other Exchanges

N/A

Address

10 High Court, Little Falls, NJ, USA, 07424

Website

https://www.regenicin.com

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines